Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Flu Vaccine Potency Remains Top Of Mind As US Panel Prepares To Pick Next Season's Strains

Executive Summary

FDA advisory committee will vote on WHO's flu strain recommendations as agency hunts for root causes of low effectiveness of current season’s vaccine. 

You may also be interested in...



Biden Wants To Release More COVID-19 Vaccine, But Also Maintain Strategic Reserve

Rather than holding half of all vaccines produced to ensure administration of the second dose, only a portion would be held to cover for manufacturing or other problems.

Universal Flu Vaccine Is Still Several Years Away, Fauci Says

Developing a universal flu vaccine will be iterative process, National Institute of Allergy and Infectious Diseases Anthony Fauci says.

Eggs May Be Culprit In Poor Flu Vaccine Performance This Year

US health authorities, manufacturers investigating why egg-based product appears to have lower effect in adults compared to cell-based flu vaccine.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1125791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel